Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new painkiller prevent breathing crises after surgery?

NCT ID NCT07753785

Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study looks at whether a newer opioid painkiller, oliceridine, is less likely than the standard sufentanil to cause breathing problems after surgery in people at high risk of obstructive sleep apnea. About 851 adults with known or suspected sleep apnea will receive one of the two drugs through a patient-controlled pump. The main goal is to see how often respiratory depression occurs within 24 hours after surgery, and whether oliceridine offers a safer option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oliceridine and sufentanil, two opioid painkillers given through a patient-controlled pump after surgery.
What this could lead to
If oliceridine proves safer, it could become a preferred painkiller for people with sleep apnea, reducing dangerous breathing complications after surgery.
What could go wrong
This is an observational study, not a randomized trial, so results may be biased. Also, oliceridine may not be widely available or may have other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 851 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with confirmed or suspected OSA who are scheduled to undergo noncardiac surgery and require patient-controlled intravenous analgesia after surgery.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 90 years. * Diagnosed with obstructive sleep apnea according to polysomnography, or suspected to be at high risk of moderate-to-severe OSA according to the STOP-Bang questionnaire: (1) STOP-Bang score ≥ 5; (2) STOP-Bang score ≥ 3 with serum bicarbonate \[HCO₃-\] ≥ 28 mmol/L; (3) STOP score ≥ 2 and male sex; (4) STOP score ≥ 2 and body mass index (BMI) \> 35 kg/m²; or (5) STOP score ≥ 2 and neck circumference \> 40 cm. * Scheduled to undergo elective non-cardiac surgery under general anesthesia. * Required patient-controlled intravenous analgesia (PCIA) after surgery. Exclusion Criteria: * Pregnant or lactating women. * Scheduled to undergo pulmonary/thoracic surgery in the current admission; * Planning to receive use of epidural analgesia. * Preplanned postoperative admission to the intensive care unit (ICU) or requirement for mechanical ventilation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obstructive sleep apnea syndrome respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obstructive sleep apnea Oliceridine Postoperative analgesia Respiratory depression Sufentanil

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University Fist Hospital

    Beijing, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.